News: SGO: Biomarkers accurate in ovarian cancer detection

Article

The measurement of two biomarkers in women with ovarian masses appears to be accurate in disginguishing which patients are most likely to have cancer.

The measurement of two biomarkers in women with ovarian masses appears to be accurate in distinguishing which patients are most likely to have cancer, allowing those patients to be referred to gynecologic oncologists for further management, according to research findings presented at the 2008 Society of Gynecologic Oncologists' Annual Meeting on Women's Cancer in Tampa, FL.

Richard Moore, MD, of Brown University in Providence, RI, and colleagues measured the blood proteins HE4 and CA125II in nearly 500 women with ovarian masses participating in a clinical trial in order to determine the biomarkers' predictive value in detecting ovarian cancer.

The researchers found that a "high-risk" test result correctly predicted 95% of cases of epithelial ovarian cancer, while a "low-risk" result correctly predicted the absence of cancer in most patients, leading to a negative predictive value of 95%.

More details on this research can be found at http:// http://www.sgo.org/content.aspx?id=58.

Recent Videos
HPV self-collection: Benefits, limitations, and future implications | Image Credit: forhers.com
Improving pediatric HPV vaccination rates: Early initiation and addressing disparities | Image Credit: blog.nemours.org.
New cervical cancer screening guidelines: What practitioners needs to know | Image Credit: forhers.com
COVID-19 Therapy Roundtable: Focusing on inpatient care
COVID-19 Therapy Roundtable: Defining the virus today and treatment options
How fezolinetant advances non-hormonal treatment of hot flashes | Image Credit: medschool.cuanschutz.edu
Contraceptive access challenges for college students in contraception deserts | Image Credit: linkedin.com.
Kameelah Phillips, MD, FACOG, NCMP, is featured in this series.
© 2024 MJH Life Sciences

All rights reserved.